Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

22/01/2025 Eastern Time in USA The Dow Jones Industrial Average rose by 0.3%, closing at 44156.73 points; the Nasdaq Composite rose by 1.28%, closing at 20009.34 points; the S&P 500 Index rose by 0.61%, closing at 6086.37 points. 

Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

REKOR SYSTEMS INC: Overnight gain 32.5%, Strategic partnership with SoundHound AI boosts stock on AI-enhanced vehicle recognition technology integration.

Rekor Systems, Inc. (NASDAQ: REKR), a Delaware corporation established in February 2017, has emerged as a leading provider of scalable and compliant outsourced support services for government and commercial clients. The company has distinguished itself in the industry by offering a comprehensive suite of solutions, setting it apart from smaller, niche service providers. Rekor's business model is strategically positioned to address the growing demand for specialized services while maintaining high standards of quality and regulatory compliance. The firm's unique approach allows it to cater to the evolving needs of its diverse client base, which spans both public and private sectors. By leveraging cutting-edge technology and industry expertise, Rekor Systems aims to streamline operations for its clients, potentially leading to improved efficiency and cost-effectiveness. As organizations increasingly seek outsourced solutions to navigate complex regulatory landscapes, Rekor's offerings are well-aligned with market trends. Investors and industry observers will likely keep a close watch on Rekor Systems as it continues to expand its footprint in the outsourced support services sector, particularly given the growing emphasis on compliance and specialized expertise across various industries.

REKOR SYSTEMS INC(REKR.US) shares surged 32.5% overnight, bringing its year-to-date gain to 33.3%, following the announcement of a strategic partnership with SoundHound AI. The collaboration aims to integrate AI voice technology into REKR's automatic license plate recognition (ALPR) systems, initially targeting police vehicles with potential expansion to fire trucks and ambulances. This innovative initiative is designed to enhance operational efficiency and safety for law enforcement and emergency response vehicles. REKR's Scout® software, compatible with existing in-vehicle high-resolution cameras, offers cost-effective ALPR services across 90+ countries and the entire United States without additional hardware requirements. The integrated system will support voice-controlled vehicle functions, significantly improving convenience and safety. These factors collectively bolstered investor confidence, driving the stock's remarkable ascent.

ABSCI CORPORATION: Overnight gain 25.2%, Innovative platform, positive ratings, pipeline progress, and ARK investment boost investor confidence

Absci Corporation, founded in Oregon in 2011 and reincorporated in Delaware in 2020, is at the forefront of revolutionizing protein development to facilitate the creation of superior and more expeditious therapeutics. The company's end-to-end integrated platform aims to supplant the fragmented processes of traditional biopharmaceutical development, thereby accelerating the progression of novel biologics into clinical trials and market launch. The biotech firm's proprietary technology is positioned to expand the boundaries of biological science, enabling the production of proteins that are challenging to obtain through conventional methods. This approach is designed to ensure that optimal drug candidates transition from concept to therapeutic reality. Absci's mission is centered on translating innovative ideas into tangible pharmaceutical solutions, with the ultimate goal of providing patients with enhanced treatment options. The company's strategic focus aligns with the growing demand for more efficient and effective drug development processes in the biopharmaceutical industry. As Absci continues to advance its platform, it potentially stands to disrupt the traditional biopharmaceutical R&D landscape, offering a streamlined approach to drug discovery and development that could significantly impact time-to-market and therapeutic efficacy.

The recent surge in ABSCI CORPORATION(ABSI.US) stock price can be attributed to multiple factors. The company's innovative biopharmaceutical development platform has garnered investor attention due to its promising business prospects. Several analysts have maintained positive ratings, with H.C. Wainwright and Guggenheim reiterating "Buy" recommendations, while Needham initiated coverage with a "Buy" rating, bolstering market confidence. Progress in ABSCI's internal drug development pipeline, particularly the potential of projects like ABS-201, has also been well-received. The company's robust financial position, with a debt-to-equity ratio below industry average, further supports investor optimism. Additionally, Cathie Wood's Ark Invest purchasing ABSCI shares through its ARKG fund has heightened investor confidence. These factors collectively drove ABSI's stock price up 25.2% in a single day, contributing to a 53.8% year-to-date gain.

GRAIL Inc. Ordinary Shares: Overnight gain 22.4%, Strong revenue guidance, robust cash reserves, and surging product demand boost investor confidence.

GRAIL, Inc., a pioneering healthcare company founded in 2015, is at the forefront of early cancer detection technology. The company has assembled a multidisciplinary team of experts to tackle one of medicine's most formidable challenges by leveraging next-generation sequencing, large-scale clinical studies, and cutting-edge computational and data science. The firm's flagship product is a multi-cancer early detection (MCED) blood test, which has shown promising results in clinical trials. This innovative diagnostic tool has demonstrated the ability to detect over 50 types of cancer from a single blood draw, with a high degree of accuracy in localizing the cancer signal. GRAIL's groundbreaking approach has the potential to revolutionize cancer diagnostics by enabling earlier detection and intervention, which could significantly improve patient outcomes and reduce healthcare costs. As the company continues to advance its technology, it is poised to make substantial inroads in the field of early cancer detection, potentially transforming the landscape of oncology and preventive medicine. Investors and healthcare professionals are closely watching GRAIL's progress, as successful commercialization of its MCED test could represent a paradigm shift in cancer screening and management strategies.

GRAIL Inc. Ordinary Shares(GRAL.US) experienced a notable surge in stock price, driven by multiple factors. The company's 2024 full-year revenue guidance exceeded market expectations, signaling robust business growth prospects. GRAL's solid financial position, particularly its $767 million cash reserve, provides a strong foundation for long-term development. The significant increase in Galleri test sales and optimistic 2025 sales projections reflect strong market demand for the product. As a recently spun-off entity from Illumina, GRAIL's performance appears to have gained market approval. Furthermore, the CEO's appearance at a high-profile medical conference bolstered investor confidence, contributing to the stock's upward momentum. These factors collectively underscore GRAIL's positive market sentiment and growth potential in the biotechnology sector.

Arm Holdings Ltd.: Overnight gain 15.9%, Surges on AI boom, semiconductor strength, potential infrastructure benefits, and analyst optimism

Arm Holdings plc, a wholly-owned subsidiary of Arm Limited, was incorporated in England and Wales in 2018. Arm Limited, founded in 1990, specializes in the design, development, and licensing of high-performance, cost-effective, and energy-efficient CPU products and related technologies. The company's intellectual property is widely adopted by numerous semiconductor firms and original equipment manufacturers (OEMs). Arm's CPU architectures are currently deployed across a diverse range of devices, including smartphones, tablets, personal computers, data centers, networking equipment, vehicles, and embedded systems such as smartwatches and thermostats. These processors power the execution of a significant portion of the world's software applications. The company's technology plays a pivotal role in the global semiconductor ecosystem, enabling innovation across various sectors of the tech industry. Arm's business model, focused on licensing rather than manufacturing, has allowed it to maintain a strong position in the rapidly evolving market for mobile and embedded computing solutions.

Arm Holdings Ltd.(ARM.US) has experienced a significant surge in its stock price, driven by multiple factors. The semiconductor industry's overall strength, particularly in AI chip-related stocks, has been bolstered by TSMC's impressive quarterly results. As a key chip design company, ARM is benefiting from the ongoing AI boom, with its stock already up 45.9% year-to-date. Furthermore, Trump's announced $5 trillion Stargate AI infrastructure investment plan is expected to boost AI-related technologies and infrastructure, potentially benefiting ARM. Barclays analysts have raised ARM's target price to $155 and maintained an "overweight" rating, reflecting positive market sentiment. These factors have collectively propelled ARM's stock price to a substantial 15.9% increase in recent trading sessions, underscoring the company's strong position in the rapidly evolving AI chip market.

The Top 10 Daily Gainers in the USA market are listed as follows:

Editor's note: This content was generated by Sahm's in-house AI-enabled SaaS tool and was reviewed by our editing team.